Core Viewpoint - Nohow Health has retained its core asset despite its delisting from the Hong Kong stock market, as it successfully renewed the medical device approval for its cancer screening product, Changweiqing, which is the first of its kind approved in China [1][2]. Group 1: Product Approval and Market Position - The "KRAS gene mutation and BMP3/NDRG4 gene methylation and fecal occult blood combined testing kit" (Changweiqing) received medical device approval, allowing Nohow Health to continue selling this product until November 2025 [2]. - Changweiqing utilizes fluorescence PCR technology and colloidal gold technology to detect mutated nucleic acid substances and hemoglobin in fecal samples, targeting high-risk populations aged 40 to 74 for colorectal cancer screening [2]. Group 2: Sales Performance - From 2020 to 2022, the revenue from Changweiqing increased from 70.6 million to 356 million yuan, with a gross margin rising from 66.9% to 83.4% [3]. - The sales volume of Changweiqing grew from 162,100 units in 2020 to 361,400 units in 2022 [3]. Group 3: Financial Scrutiny and Challenges - In August 2023, CapitalWatch released a short-selling report alleging serious financial fraud by Nohow Health, claiming inflated sales figures and excessive inventory [4]. - The report indicated that in 2022, Changweiqing was sold in approximately 26 public medical institutions, with an estimated annual sales revenue of about 3 million yuan, significantly lower than reported figures [4][7]. - CapitalWatch's investigation revealed that the product's actual sales performance in both public and private medical institutions was far below the disclosed financial data [4][7]. Group 4: Investor Concerns and Legal Actions - Following the delisting, investors are focused on how to recover losses, with over 3,216 investors registering claims totaling more than 700 million HKD [9]. - The company is currently seeking suitable liquidators to initiate liquidation proceedings in Hong Kong, despite being registered in the Cayman Islands [10].
“暴雷”后的诺辉健康保住癌症早筛第一证